3SBio Inc. Announces Unaudited Second Quarter 20...(MB54.3 million (US$7.9 million) for the ...),Health

Operating expenses. GAAP operating expenses were RMB49.2 million (US$7.2 million) for the second quarter of 2009, an increase of 25.8% from GAAP operating expenses of RMB39.1 million (US$5.7 million) for the same period in 2008. Non-GAAP operating expenses were RMB48.0 million (US$7.0 million) for the second quarter of 2009, an increase of 28.2% from non-GAAP operating expenses of RMB37.4 million (US$ 5.5 million) for the same period in 2008. The increase in operating expenses was largely driven by higher sales and marketing expenses.

    -- Research and development ("R&D") costs. GAAP R&D costs for the second
       quarter of 2009 were RMB4.3 million (US$0.6 million), or 5.2% of net
       revenue, compared to RMB3.0 million (US$0.4 million), or 5.1% of net
       revenue for the same period in 2008.
    -- Sales, marketing and distribution expense. GAAP sales, marketing and
       distribution expenses for the second  quarter of 2009 were
       RMB36.2 million (US$5.3 million), compared to RMB26.6 million
       (US$3.9 million) for the same period in 2008. The increase was
       primarily attributable to higher sales activities in general, continued
       investment in building the TPIAO brand and EPIAO penetration of the
       oncology market. This represented 44.5% of net revenue, almost
       unchanged from 44.6% for the same period in 2008.
    -- General and administrative expenses. GAAP general and administrative
       expenses for the second quarter of 2009 were RMB8.7 million
       (US$1.3 million), representing a decrease of 8.7% from general and
       administrative expenses of RMB9.5million (US$1.4 million) for the same
       period in 2008. This marked a decline to 10.6% of net revenue for the
       second quar
'/>"/>
SOURCE  3SBio Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
Related medicine news :

1. 3SBio Inc. to Report 2009 Second Quarter Earnings on August 11, 2009
2. 3SBio Inc. Announces Unaudited First Quarter 2009 Results
3. 3SBio Inc. Files for SFDA Approval for TPIAO Label Extension for the Treatment of ITP
4. 3SBio Inc. Announces Filing of Annual Report on Form 20-F
5. 3SBio Inc. to Present at The CIBC World Markets 18th Annual Healthcare Conference
6. Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results
7. Webmedx Announces That CEO Sean Carroll Has Been Appointed to the AHIMA Foundation Board of Directors
8. Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
9. Leading Medical Developer Announces Plans for Texoma Medical Plaza
10. iMedX Announces Investment of $13M From RFE Investment Partners
11. Health Market Science Announces Commercial Release of CompleteSpend V2.5